Floatz logo

ap203

Esophageal Squamous Cell Carcinoma (ESCC)

AP Biosciences Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

64 Active assets in the Esophageal Squamous Cell Carcinoma (ESCC) cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
AstraZeneca
Phase 3BB
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

ap203 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Locally Advanced or Metastatic Solid TumorsDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →